In the context of cancer immunotherapy, agents that target the immune system to cancer cells need to fulfil two criteria: 1) that they are only expressed on the desired target cell and 2) that they can elicit a potent immunological response. Cancer Testis Antigens are a large disparate family of factors ordinarily expressed in the germ-line but aberrantly expressed across multiple types of cancer. The ability to enforce their expression on tumour cells is an attractive strategy that could render such cells potent targets of the immune system, but very little is known about their regulation. We describe the generation of an mCherry reporter cell line using HCT116 colorectal carcinoma cells that we anticipate will be useful for screen-based approaches to identify novel regulators of CTA expression. Discoveries arising from their use could in future be exploited to enhance tumour cell immunogenicity and improve cancer immunotherapy.
Introduction
Harnessing the body's immune system to target and destroy cancer cells holds great promise in the war on cancer and this strategy has recently been shown to be highly effective in clinical trials [1] . Cancer vaccines, a type of immunotherapy, involve exposing the immune system to highly immunogenic, cancer-specific antigens, that subsequently activate both the cellular and humoral branches of the immune system, resulting in the targeted destruction of diseased tissue. Cancer testis antigens (CTA) are a large, disparate family of factors ordinarily expressed in the human germ-line and placenta, with key functions in reproduction and the cell cycle [2] .
CTAs were originally identified by autologous typing and serological analysis of cDNA expression libraries (SEREX), which involves the use of a patients' own cytotoxic T-lymphocytes (CTLs) and antibodies respectively, to recognise and respond to antigens produced by their own tumour cells. Originally, 265 unique CTAs classified into 58 different families were identified [3] but a recent study using publically-available data from The Cancer Genome Atlas (TCGA) as well as three separate transcriptomics data sets (The Genotype-Tissue Expression (GTex) Project, Ilumina Human BodyMap 2.0 and Nanjing University Medical University (NJMU) RNA-seq Database) suggests the CTA designation might be applicable to many more factors [4] , although it remains unclear whether all of these transcripts can be translated into protein. Typically, CTAs are only expressed in the testis and placenta, and if they are detected in other non-diseased tissues, their expression level is substantially lower than that observed in their native organ.
The testis is an immune-privileged site: the blood-testis barrier combined with the absence of HLA Class I presentation on the surface of germ cells prevents the immune system from interacting and recognising CTAs as self during the establishment of central tolerance [5] . Therefore, from an immunological perspective, CTAs are essentially tumour-specific and hold great promise for cancer vaccines and immunotherapy.
The CTA NUF2 (also known as Cell Division Cycle-Associated Protein 1 CDCA1) is a highly conserved protein originally identified in S. cerevisiae and crucial for normal chromosome segregation [6] . As a component of the kinetochore, it is required for the formation of stable microtubule-kinetochore attachments, chromosome alignment and the spindle checkpoint during mitosis in mammalian cells [7] . As well as results from TCGA data, NUF2 overexpression has been reported in a diverse set of cancers including pancreatic [8] , gastric and colorectal [9] , lung (both small cell and non-small cell), cholangiocellular, urinary bladder and renal [10, 11] . The functional importance of NUF2 in cancer is suggested through screen based studies; an RNAi lethality screen in the Epithelial Ovarian Cancer (EOC) cell line A1847 and other EOC lines identified the factor as important for preventing apoptosis [12] . Analysis of mutations in the PanCancer compendium data set of 4,742 tumours from 21 cancer types revealed mis-sense mutations in NUF2 that could affect chromosome segregation and result in aneuploidy [13] . Proof of the immunogenicity and potential utility of enforcing NUF2 expression for therapeutic purposes comes from a study demonstrating that NUF2 can activate both CD4þ/T h 1 and CTLs [14] . HLA-A24(A*24:02) or HLA-A2(A*02:01)-restricted CTL epitopes were identified that induced tumour-reactive CTLs but not autoimmunity; these epitopes were found to correspond to NUF2 protein. Importantly, long peptides were identified that were capable of activating both T h 1 and CTLs.
Despite their general expression across multiple types of cancers, an outstanding issue is that CTA expression is heterogeneous i.e. not all cases of a particular cancer present with CTA expression, and even within tumors that express or upregulate CTA expression, expression does not occur uniformly within all cells [15] . Epigenetic mechanisms, particularly 5-methyl cytosine (5mC) found in CG contexts (DNA methylation), appear to be involved in CTA silencing. The general DNA demethylating drug, 5 0 -aza-2 0 deoxycytidine (5-AZA-CdR) activates MAGE-A1 expression in human melanoma cells [16] . Studies in mouse indicate that promoter methylation arises during preimplantation development [17] and recent studies indicate the importance of transcription factor binding in driving the loss of DNA methylation marks around promoter regions [18] whilst its presence can antagonise transcription factor binding [19] . These observations are consistent with a model whereby transcription factors play a dominant role in activating CTA expression, followed by the loss of DNA methylation that may assist in maintaining gene activation.
Forward based screens, for example using the CRISPR/Cas9 system and single guide RNAs (sgRNAs), provide a powerful means of identifying novel factors functionally involved in biological processes [20] . How CTAs are correctly regulated remains poorly defined and improvements in our understanding of the basic mechanisms involved will be crucial in the future development of targeted cell therapies designed to activate their expression in non-expressing cells. Using CRISPR/ Cas gene editing, we describe the generation of a NUF2-mCherry reporter in HCT116 colorectal carcinoma cells. We propose that these cells will be of utility in screen-based approaches to identify novel regulators of CTA expression. 
HCT116 cell culture
Cells were cultured in HCT116 cell media which consisted of Dulbecco modified Eagle medium (DMEM) supplemented with 100 IU/ml penicillin and 10% fetal bovine serum. Cell counting was performed using Muse TM Count & Viability Kit (Millipore) on a Muse TM Cell Analyzer (Millipore).
qRT-PCR analysis of NUF2 expression
For HCT116 cells, RNA was extracted using Trizol reagent (Thermo Fisher Scientific). For human lung, RNA was prepared using AllPrep RNA/Protein Kit (Qiagen). Human Testis total RNA was purchased from Clonetech. Except for lung RNA, RNAs were additionally treated with Turbo DNase (Thermo Fisher Scientific). First strand cDNA was generated using Maxima Reverse Transcriptase (Thermo Fisher Scientific) and oligo(dT) 18 primers according to the manufacturer's protocol. cDNAs were diluted 1:10 and used for qRT-PCR using the Roche Universal Probe Library System (Roche). Primers compatible with hydrolysis Probe 8 were used and GAPDH probe and primer set used as the reference gene control. Reactions were run on a LightCyclerÒ 480 II (Roche).
Transfection of HCT116 cells
The day before transfection, 2.5 Â 10 5 cells were seeded onto the well of a 24 well plate. On the day of transfection, cells were transfected using Fugene 6 transfection reagent (Promega) according to the manufacturer's protocol. Per transfection, a total of 1 mg of DNA was used. This consisted of hCas9 plasmid (400 ng) [24] , a synthetic gRNA expression cassette containing NUF2 gRNA (300 ng), an mCherry CDScontaining replacement cassette (200 ng) and a synthetic gRNA expression cassette containing HRPT gRNA (100 ng). The latter was included to enrich for transfected cells by culture in 6-Thioguanine (6-TG) containing media. Synthetic gRNA expression cassettes were designed as described by Mali and colleagues [24] . 16 to 18 hours post transfection, cells were harvested, counted and seeded onto four 15 cm plates (2 Â 10 5 cells/plate). Three days after seeding, media was replaced with 6-TG containing media (final concentration, 10 mg/ml). Fresh 6-TG containing media was replaced every four days. Twelve days after initial transfection, individual colonies were identified by eye, picked and cultured in flat-bottom 96-well plates. Cells were expanded for DNA preparation and continued culture.
PCR screening and sequencing
Genomic DNA from confluent 96 well plates was prepared using Quick-DNA TM 96
Kit (Zymo Research) according to the manufacturer's protocol. PCR was performed using KAPA2G Robust HotStart PCR Kit (Kapa Biosystems) according to the manufacturer's protocol with the inclusion of Enhancer reagent. For the generation of amplicons for Sanger sequencing, PCR was optimised using Phusion HighFidelity DNA Polymerase (Thermo Fisher Scientific) and gel resolved amplicons purified using MinElute Gel Extraction Kit (Qiagen) according to the manufacturer's protocol.
Sequences
For screening/genotyping PCRs, the following primers were used (listed 5 0 to 3 0 ):
The sgRNA sequences used for targeting hCas9
were: NUF2_gRNA14 (CGGTATTGAAAAGGCAGCAGAGG), HPRT_gRNA (aaagtaattcacttacagtctgg). For NUF2 qRT-PCR, the primers used were: NUF2_8_F (ccagacaagaagtggtggaga) and NUF2_8_R (tgatataactgcacttccaactgac).
Antibodies
The following antibodies were used at the dilutions indicated: Anti-Tubulin
(1:10,000, T6199, Sigma-Aldrich), Anti-RFP (1:700, 6G9, Chromotek) and Anti-NUF2 (1:100, sc-271-251, Santa Cruz).
Western blot
Pelleted cells (fresh or snap-frozen) were lysed in RIPA buffer (1 Â PBS, 1 % NP40, 0.5% Sodium Doxycholate, 0.1% SDS). Samples were quantified using Bio-Rad Protein Assay (Bio-Rad) and equal amounts (50 mg) of lysate were loaded onto 8% 
FACS analysis

Cell cycle and viability analysis
Cultured HCT116 and NUF2 mCherry/mCherry cells were harvested and labelled using 
Cell imaging
Images of live cells in culture were acquired on a Zeiss Axio Observer Z1 (Carl Zeiss) microscope. For confocal imaging, cells were harvested, fixed in 2% PFA and seeded by centrifugation (800 rpm, 4 minutes) onto coated slides using a Shandon Cytospin (Thermo Fisher Scientific). After briefly washing with 1 Â PBS, VEC-TASHIELD Antifade Mounting Medium with DAPI (Vectorlabs) was applied and slides covered with cover slips. Images were acquired on an LSM 880 with Aryscan microscope (Zeiss).
Results and discussion
Analysis of The Cancer Genome Atlas (TCGA) data revealed that the CTA NUF2 is consistently over-expressed across a broad range of different cancer types (Fig. 1A) .
Analysis of publicly available RNA-Seq data through the GTex Portal indicates that normal colon has low levels of NUF2 expression, similar to that observed in normal lung (Fig. 1B) . qRT-PCR confirmed that whilst NUF2 expression is undetectable in non-germ line tissue (in this case lung), it is 2-3 orders of magnitude higher in both testis and the colorectal carcinoma cell line, HCT116 (Fig. 1C) . To generate a reporter cell line as a tool for screen-based approaches to identify novel regulators of NUF2 expression, we used CRISPR/Cas editing to introduce an mCherry CDS into the endogenous NUF2 locus of HCT116 colorectal carcinoma cells to generate an in-frame fusion protein.
As this gene has a promoter-associated CpG island that may be involved in regulating its expression, the mCherry CDS was added to the Cterminus, immediately before the endogenous STOP codon in exon 14 (Fig. 1D ).
CHOPCHOP web tool was used to identify a suitable sgRNA sequence, close to the STOP codon. To enrich for successfully targeted cells, an sgRNA targeting the HPRT locus which has previously been used in HCT116 cells was also included [25] . Two separate transfections were performed and a total of 576 colonies were picked and screened by PCR, initially using primers to detect the mCherry CDS.
13 clones were found to carry the mCherry reporter and were expanded up for further analysis. Using the primers indicated in Fig. 1C and D, which are external to the regions used for the homology arms, PCR on DNA extracted from one clone (P1_E2) generated amplicons at the expected sizes following successful targeting ( Fig. 1E and Supplemental Fig. S1 ). PCR using primers 5 0 F þ WTR, designed to detect the wildtype untargeted allele failed to generate an amplicon at the expected size indicating these cells are homozygous for insertion of the mCherry reporter; these cells are hereafter referred to as NUF2 mCherry/mCherry (mC/mC).
The strategy of using an mCherry CDS lacking various elements necessary for successful transcription (i.e. promoter, start ATG, stop codon, polyadenylation signal) was to ensure that mCherry expression would only be detected following correct insertion into the NUF2 locus in the manner anticipated. Expression of NUF2-mCherry fusion protein was confirmed using several approaches. Western blot analysis was performed on whole cell extracts/RIPA lysates using both anti-RFP and anti-NUF2 antibodies. NUF2 protein is predicted to be approximately 54 kDa; the inclusion of mCherry generates an approximately 80kDa protein and an immunoblot signal was observed at this size in mC/mC cells ( Fig. 2A and Supplemental Fig. S2 ).
This result was recapitulated when lysates were probed with anti-NUF2 antibody. In addition to the fact that the size of the band is increased in mC/mC cells, we note the presence of a non-specific band approximately 60kDa in size ( Fig. 2A , *) present in both the untargeted parental HCT116 and mC/mC cells. Analysis of live cells by fluorescence microscopy indicated robust mCherry expression (Fig. 2B) . NUF2 is known to have a major function during metaphase to ensure microtubules correctly attach to kinetochores. We further examined the subcellular localisation of NUF2-mCherry protein by confocal microscopy (Fig. 2C) . In interphase cells, NUF2- These results agree with earlier studies examining the sub-cellular distribution of GFP-tagged NUF2 protein in DT40 cells [26] , and suggest that NUF2-mcherry protein is capable of correct localisation during the cell cycle.
We next assessed the ability to detect NUF2-mCherry signal by FACS. The mCherry expression profile for mC/mC cells, was shifted relative to signal observed in parental, untargeted HCT116 cells (Fig. 3A) . Cell cycle analysis of live-gated cells using a fluorescent DNA dye (DRAQ5 TM ) revealed that mCherry is expressed throughout the cell cycle (Fig. 3B) , consistent with our immunofluorescence data.
Quantitative analysis of the percentage of cells at different stages of the cell cycle revealed a significant increase in cells in both G1 and S phase with a concomitant reduction in the proportion in G2/M phase (Fig. 3C) . Combined with our microscopy data, this suggests that although NUF2-mCherry correctly localises during mitosis, the presence of the mCherry moiety may be affecting NUF2 function. The human genome reportedly encodes twenty cyclin dependent kinases (CDKs) and twentynine cyclins (CLNs) [27] . While we cannot formally exclude any direct effect on the levels of the various cyclin proteins expressed throughout the cell cycle, correct NUF2 function is known to be required for the formation of stable microtublekinetochore attachments and subsequent passage through the mitotic spindle checkpoint. As these processes are regulated by Cyclin A proteins [28] , we consider these to be candidate cyclins whose expression is perturbed by the presence of the mCherry moiety on NUF2 protein. Despite this effect on the cell cycle, this did not translate to any significant effect on cell viability (Figs. 3D and E).
The successful exploitation of CTAs for use in cancer vaccines requires improvements in our understanding of how these factors are regulated. Mammalian gametogenesis, particularly spermatogenesis is a highly controlled process and there is likely to be co-ordinate regulation of these factors. Presently, little is known about how NUF2 expression is regulated at the transcriptional level. A single, previous study in HCT116 cells claimed that the highly abundant protein heterogeneous nuclear ribonucleoprotein K (HNRNPK) is an important transcriptional activator of NUF2 [29] . Despite a number of attempts, we have been unable to generate HNRNPK-deficient cells in order to both validate the role of HNRNPK in regulating NUF2 expression as well as to serve as a positive control in order to test our cell line.
However, we anticipate that the cell line described in this present study will serve as a useful tool in future screen-based approaches designed to identify novel regulators of NUF2 expression.
We note that these labelled cells could also be suitable for tracking purposes in preclinical mouse models of colorectal cancer. HCT116 and other colorectal cancer cell lines have been successfully used in a number of transplantation models involving immunodeficient mice, using both subcutaneous and orthotopic xenografts [30] .
Labelling studies have also been performed involving the transduction of colorectal cancer cell lines with fluorescent reporter transgenes and injecting/implanting polyclonal populations of such cells [31, 32] , which are likely to have variable reporter expression. The fact that the reporter cell line we have generated carries the mCherry reporter fused to an endogenous gene, controlled by its endogenous regulatory elements indicates more physiological and more importantly, stable regulation of reporter expression. This would be an important and useful feature for longitudinal studies. As mCherry fluorescence from these cells is readily detectable by FACs, these cells would be useful in monitoring and quantifying the spread of tumour growth both within organs and possibly by metastasis. They could therefore serve as a tool for preclinical studies testing the effectiveness of different therapeutic strategies. Finally, the presence of the mCherry moiety fused to NUF2 could be utilised for both live cell imaging and protein purification studies designed to further investigate mammalian mitosis.
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